呈和科技(688625)：归母净利润延续稳健增长 成核剂国产替代有望提速

Group 1 - The company achieved operating revenue of 882 million yuan in 2024, a year-on-year increase of 10.31%, and a net profit attributable to shareholders of 250 million yuan, up 10.68% year-on-year [1] - The sales net profit margin was 28.37%, an increase of 0.09 percentage points year-on-year, with the main product, nucleating agents, generating revenue of 511 million yuan, a growth of 24.09% [1] - The company’s nucleating agent sales volume reached 9,727.54 tons, a year-on-year increase of 32.03%, with a gross margin of 55.91%, down 1.12 percentage points [1] Group 2 - The company’s nucleating agent production capacity has doubled following the completion of its IPO fundraising projects, with a total capacity of 14,400 tons per year approved and operational since January 2024, and an additional 14,500 tons per year starting production testing in November 2024 [1] - The company plans to acquire at least 51% of Wuhu Yingri Technology Co., Ltd. for cash, with an estimated total valuation of 1.8 billion yuan, which will enhance its presence in the display materials sector [2] - The domestic nucleating agent import substitution rate is expected to accelerate due to the 125% tariff imposed on U.S. imports, with the company positioned to benefit from increased demand for domestic products [2]